Elevated serum vitamin B 12 levels in association with tumor markers as the prognostic factors predictive for poor survival in patients with hepatocellular carcinoma

Nutrition and Cancer

Volumn 62, Issue 2, 2010, Pages 190-197

  Lin, Ching Yih ^a   Kuo, Chang Sheng ^a,b   Lu, Chin Li ^a   Wu, Meng Ying ^b   Huang, Rwei Fen Syu ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; CYANOCOBALAMIN; HEMOGLOBIN; TUMOR MARKER;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PREDICTION; PROGNOSIS; RADIOIMMUNOASSAY; TAIWAN; TUMOR GROWTH; TUMOR VOLUME; VITAMIN BLOOD LEVEL;

AGED; ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ANALYSIS OF VARIANCE; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DIET; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBINS; HUMANS; LIFE STYLE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SERUM ALBUMIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VITAMIN B 12;

EID: 76749157578     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580903305334     Document Type: Article

References (43)

1. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, and Thomas HC: Increase in primary liver cancer in the UK, 1979-1994. Lancet 350, 1142-1143, 1997.
2. El Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340, 745-750, 1999.
3. Parkin DM, Bray F, Ferlay J, and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 94, 153-156, 2001. (Pubitemid 32911406)
4. Ng IO, Lai EC, Fan ST, Ng MM, and So MK: Prognostic significance of pathologic features of hepatocellular carcinoma. Cancer 76, 2443-2448, 1995.
5. Terris B, Laurent-Puig P, Belghitti J, Degott C, H́enin D, et al.: Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in France. Int J Cancer 74, 614-619, 1997.
6. Nagaoka S, Yoshida T, Akiyoshi J, Akiba J, Torimura T, et al.: Serum Creactive protein levels predict survival in hepatocellular carcinoma. Liver Int 27, 1091-1097, 2007.
7. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, et al.: Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the steering committee of the European Association for Palliative Care. J Clin Oncol 23, 6240-6248, 2005.
8. Shimizu Y, Nagaya N, Isobe T, Imazu M, Okumura H, et al.: Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 9, 774-778, 2003.
9. Kuo CS, Lin CY, Wu MY, Lu CL, and Huang RF: Relationship between folate status and tumour progression in patients with hepatocellular carcinoma. Br J Nutr 100, 596-602, 2008.
10. Baker H, Frank O, and DeAngelis B: Plasma vitamin B12 titres as indicators of disease severity andmortality of patients with alcoholic hepatitis. Alcohol 22, 1-5, 1987.
11. Lindemans J, Abels J, Neijens HJ, and Kerrebijn KF: Elevated vitamin B12 in cystic fibrosis. Acta Paediatr Scand 73, 768-771, 1984. (Pubitemid 15209678)
12. Majumdar SK, Shaw GK, O'Gorman P, Aps EJ, Offerman EL, et al.: Blood vitamin status (B1, B2, B6, folic acid and B12) in patients with alcoholic liver disease. Int J Vitam Nutr Res 52, 266-271, 1982.
13. Chen CJ, Yu MW, and Liaw YF: Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatology 12, S294-S308, 1997.
14. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, et al.: Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-an analysis of 236 consecutive patients with a single lesion. Hepatology 32, 1216-1223, 2000.
15. Osifo BO, Ayoola A, Parmentier Y, Gerard P, and Nicolas JP: Correlation between serum enzymes and serum unsaturated vitamin B12 binding proteins in primary liver carcinoma. Enzyme 39, 161-166, 1988.
16. Fremont S, Chamigneulle B, Gerard P, Felden P, Lambert D, et al.: Blood transcobalamin levels in malignant hepatoma. Tumor Biol 12, 353-359, 1991.
17. Nexo E, Olesen H, Norredam K, and Schwartz M: A rare case of megaloblastic anaemia caused by disturbances in the plasma cobalamin binding proteins in a patient with hepatocellular carcinoma. Scand J Haemtol 14, 320-327, 1975.
18. Carmel R and Eisenberg L: Serum vitamin B12 and transcobalamin abnormalities in patients with cancer. Cancer 40, 1348-1353, 1977.
19. Ermens AA, Vlasveld LT, and Lindemans J: Significance of elevated cobalamin (vitamin B12) levels in blood. Clin Biochem 36, 585-590, 2003.
20. Geissbühler P, Mermillod B, and Rapin CH: Elevated serum vitamin B12 levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. J Pain Symptom Manage 20, 93-103, 2000.
21. Kelly L, White S, and Stone PC: The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study. Ann Oncology 18, 1395-1399, 2007.
22. Greene FL, Balch CM, Page DL, Haller DG, Fleming ID, et al.: TNM classification of malignant tumors. In: Cancer Staging Handbook, Greene FL (ed.), 6th ed. New York: Berlin Heidelberg, 2002, pp. 142-154.
23. Kao CS: Relationships between vitamin status, plasma homocysteine and hepatitis in Taiwanese population. Master's thesis, Department of Nutritional Science, Fu-Jen University, Hsin-Chuang, Taiwan, 2003.
24. Kaplan EL andMeier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53, 457-481, 1958.
25. Wu MY, Kuo CS, Lin CY, Lu CL, and Huang RFS: Lymphocytic mitochondrial DNA deletions, biochemical folate status and hepatocellular carcinoma susceptibility in a case-control study. Br J Nutr 102, 715-721, 2009.
26. Stabler SP, Allen RH, Savage DG, and Lindenbaum J: Clinical spectrum and diagnosis of cobalamin deficiency. Blood 76, 871-881, 1990.
27. Bolann BJ, Solli JD, Schneede J, Grøttum KA, Loraas A, et al.: Elevation of indicators of cobalamin deficiency defined as cobalamin-induced reduction in increased serum methylmalonic acid. Clin Chem 46, 1744-1750, 2000.
28. Hall CA: The transport of vitamin B12 from food to use within the cells. J Lab Clin Med 94, 811-816, 1979.
29. Djalali M, Champigneulle B, Gueant JL, Kholty S, Gerard P, et al.: Increased serum corrinoids correlates with disease severity and IgA levels in alcoholic cirrhosis. Digestion 41, 215-222, 1988.
30. Kanazawa S and Herbert V: Total corrinoid, cobalamin and cobalamin analogue levels may be normal in serum despite cobalamin in liver depletion in patients with alcoholism. Lab Invest 53, 108-110, 1985.
31. Linnell JC, Quadros EV,Matthews DM, Morris HP, and Poirier LA: Altered cobalamin distribution in rat hepatomas and in the livers of rats treated with diethylnitrosamine. Cancer Res 37, 2975-2978, 1977.
32. Bruera E and Sweeney C: Cachexia and asthenia in cancer patients. Lancet Oncol 1, 138-147, 2000.
33. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu YM, et al.: High alphafetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer 112, 44-50, 2004.
34. Kane SP,Murray-Lyon IM, Paradinas FJ, Johnson PJ,Williams R, et al.: Vitamin B12 binding protein as a tumor marker for hepatocellular carcinoma. Gut 19, 1105-1109, 1978.
35. Kanai T, Takabayashi T, Kawano Y, Kuramochi S, and Miyazawa N: A case of postoperative recurrence of fibrolamellar hepatocellular carcinoma with increased vitamin B12 binding capacity in a young Japanese female. Jpn J Clin Oncol 34, 346-351, 2004.
36. Yamasaki T, Kimura T, Kurokawa F, Aoyama K, Ishikawa T, et al.: Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 40, 70-78, 2005.
37. Calvet X, Bruix J, Gińes P, Bru C, Soĺe M, et al.: Prognostic factors of hepatocellular carcinoma in theWest: amultivariate analysis in 206 patients. Hepatology 12, 753-760, 1990.
38. Hsu HC, Sheu JC, Lin YH, Chen DS, Lee CS, et al.: Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan: a comparison with resected large HCC. Cancer 56, 672-680, 1985.
39. Nomura F, Ohnishi K, and Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alphafetoprotein levels: analysis of 606 patients. Cancer 64, 1700-1707, 1989.
40. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, et al.: Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 6, 385-391, 1991.
41. Izumi R, Shimizu K, Kiriyama M, Hashimoto T, Urade M, et al.: Alphafetoprotein production by hepatocellular carcinoma is prognostic of poor patient survival. J Surg Oncol 49, 151-155, 1992.
42. Pompili M, Rapaccini GL, Covino M, Pignataro G, Caturelli E, et al.: Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 92, 126-135, 2001.
43. Hanazaki K, Kajikawa S, Koide N, Adachi W, and Amano J: Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis. Am J Gastroenterol 96, 1243-1250, 2001.